Given the recent developments that have revealed an allosteric site exists on the MKPs that render them druggable79–81, these data raise the possibility that MKP1 may represent a potential therapeutic target to curtail the progression of NASH. This evidence concerns the gene DUSP1 and metabolic dysfunction-associated steatohepatitis.